ESMO 2017: News Articles

Interested in what happened during the ESMO 2017 Congress?

Read our news articles here

Date Title Topic
11 Sep 2017 ESMO 2017: Adjuvant Dabrafenib Plus Trametinib Significantly Lowers Risk of Death in Stage III BRAF V600–Mutated Melanoma Melanoma and other skin tumours - Anticancer agents & Biologic therapy
11 Sep 2017 ESMO 2017: Nivolumab Bests Ipilimumab as Adjuvant Therapy in Resected Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: BRIM8 Data Shows Benefit with Adjuvant Vemurafenib in Resected BRAFV600 Positive Melanoma Melanoma and other skin tumours - Anticancer agents & Biologic therapy
11 Sep 2017 ESMO 2017: Single Agent Atezolizumab in Head and Neck Cancer Head and neck cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: Nivolumab Demonstrates Antitumour Activity Post-progression in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Head and neck cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: Durvalumab Shows Promising Clinical Benefit in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Head and neck cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer Head and neck cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: Rocapuldencel-T Shows Potential Benefit in Metastatic Renal Cell Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: First-line Dabrafenib and Trametinib Shows Substantial Clinical Activity in BRAF V600E–mutated Metastatic NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: First KEYNOTE-028 Report of Pembrolizumab Activity in Patients with PD-L1-positive pNETs and Carcinoid Tumours Endocrine and neuroendocrine tumours - Cancer Immunology and Immunotherapy
10 Sep 2017 ESMO 2017: Immune Landscape of PanNETs Endocrine and neuroendocrine tumours - Pathology/Molecular biology
10 Sep 2017 ESMO 2017: Improved Survival Demonstrated with NSCLC-chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma with RB1 Wild-type Endocrine and neuroendocrine tumours - Translational research
10 Sep 2017 ESMO 2017: Location of the Primary Tumour, but not KRAS Mutations, May Indicate SIRT Survival Benefit in mCRC Gastrointestinal cancers
10 Sep 2017 ESMO 2017: Pembrolizumab Continues to Show Greater Benefit over Chemotherapy in Recurrent, Advanced Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
10 Sep 2017 ESMO 2017: Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy